List of Excipients in Branded Drug DOCETAXEL ANHYDROUS

Generic Drugs Containing DOCETAXEL ANHYDROUS

Company	Ingredient	NDC	Excipient
Meitheal Pharmaceuticals Inc	docetaxel anhydrous	71288-143	ALCOHOL
Meitheal Pharmaceuticals Inc	docetaxel anhydrous	71288-143	ANHYDROUS CITRIC ACID
Meitheal Pharmaceuticals Inc	docetaxel anhydrous	71288-143	POLYETHYLENE GLYCOL 300
Meitheal Pharmaceuticals Inc	docetaxel anhydrous	71288-143	POLYSORBATE 80
Meitheal Pharmaceuticals Inc	docetaxel anhydrous	71288-144	ALCOHOL
Meitheal Pharmaceuticals Inc	docetaxel anhydrous	71288-144	ANHYDROUS CITRIC ACID

What are the Most Frequently-Used Excipients in DOCETAXEL ANHYDROUS?

# Of NDCs	Excipient
4	ALCOHOL
4	ANHYDROUS CITRIC ACID
4	POLYETHYLENE GLYCOL 300
4	POLYSORBATE 80

Docetaxel Anhydrous Excipient Strategy and Commercial Opportunities

Last updated: August 23, 2026

Docetaxel anhydrous is a small-molecule taxane used in injectable chemotherapy products for breast, prostate, gastric, head and neck, and non-small-cell lung cancers. The active ingredient is commercially established, genericized, and highly price competitive. The strongest opportunities are not in the molecule itself, but in excipient-enabled delivery systems that reduce polysorbate 80 exposure, eliminate ethanol, improve stability, simplify administration, or enable non-intravenous dosing.

Docetaxel has low aqueous solubility, a narrow therapeutic index, formulation-related hypersensitivity concerns, and a demanding infusion workflow. These constraints create commercial space for ready-to-use solutions, solvent-free formulations, nanoparticle systems, oral delivery, and differentiated hospital products.

What is docetaxel anhydrous and how is it used?

Docetaxel anhydrous is the water-free form of docetaxel, a semisynthetic taxane that stabilizes microtubules and inhibits cell division. Its molecular formula is C43H53NO14, with a molecular weight of approximately 807.88 g/mol. The compound is also identified by CAS Registry Number 148408-66-6.

The reference product, Taxotere, is administered intravenously after dilution. FDA labeling identifies breast cancer, non-small-cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer indications for specified regimens and combinations.[1]

Docetaxel is practically insoluble in water. The commercial formulation challenge is therefore not simply drug loading. It includes:

• Solubilization at clinically useful concentrations
• Prevention of precipitation after dilution
• Control of oxidation, hydrolysis, and aggregation
• Reduction of infusion-related reactions
• Compatibility with bags, syringes, filters, and infusion sets
• Reproducible dose delivery at low concentrations
• Practical storage and handling in oncology pharmacies

Which excipients are used in conventional docetaxel injections?

Conventional docetaxel injections use a solvent system based on polysorbate 80 and ethanol. The concentrate is diluted before intravenous administration.

Formulation element	Commercial role	Main limitation
Docetaxel anhydrous	Active pharmaceutical ingredient	Very low water solubility
Polysorbate 80	Solubilizer and surfactant	Hypersensitivity, micelle-related tolerability, oxidation and peroxide formation
Ethanol	Co-solvent	Alcohol exposure, handling restrictions, flammability, patient-specific tolerability
Dilution solution	Administration vehicle	Precipitation and concentration control
Infusion container and set	Dose delivery	Adsorption, leachables, compatibility and hold-time risks

Polysorbate 80 is central to the legacy formulation but creates a recognized product-differentiation target. FDA labeling for Taxotere includes warnings concerning hypersensitivity reactions and fluid retention, with corticosteroid premedication used to reduce certain treatment-related effects.[1] The excipient system may contribute to infusion complexity even when the pharmacological toxicity is attributable primarily to docetaxel.

Ethanol can also create operational issues. Product labeling instructs healthcare professionals to account for alcohol content, particularly in patients for whom alcohol exposure is clinically relevant.[1]

What excipient strategy best fits docetaxel anhydrous?

The strongest development strategy depends on the commercial claim being pursued.

Strategy 1: Improve the conventional solvent system

A reformulated concentrate can preserve the existing infusion route while reducing excipient burden. Potential approaches include:

• Lower polysorbate 80 concentration
• Alternative nonionic surfactants
• Mixed surfactant systems
• Ethanol reduction or replacement
• Antioxidant protection
• Buffer optimization
• Improved container closure and oxygen control

This is the lowest-risk route because it preserves oncology workflow and established intravenous dosing. Its weakness is limited differentiation if the formulation still requires dilution, premedication, and infusion monitoring.

Candidate excipient classes include poloxamers, polyoxyl castor oil alternatives, phospholipid systems, cyclodextrins, and carefully selected lipidic solubilizers. Each requires assessment for hemolysis, complement activation, extractables, leachables, degradation products, and compatibility with infusion materials.

Strategy 2: Develop a solvent-free nanodispersion

Nanoparticle, nanosuspension, liposomal, polymeric micelle, and albumin-associated systems can reduce or eliminate polysorbate 80 and ethanol. The commercial objective is usually one or more of the following:

• Higher drug concentration
• Ready-to-use administration
• Reduced infusion time
• Lower hypersensitivity burden
• Improved tumor exposure
• Reduced need for corticosteroid premedication
• Better physical stability after dilution

The technical risk is higher than for a conventional reformulation. Critical quality attributes include particle size distribution, polydispersity, surface charge, free-drug fraction, encapsulation efficiency, release profile, sterility, endotoxin, and dose uniformity.

A nanocarrier does not automatically improve clinical safety. Changes in tissue distribution, macrophage uptake, clearance, and infusion reactions must be demonstrated clinically. FDA review will focus on comparative quality, pharmacokinetics, immunogenicity-like reactions associated with the carrier, and whether clinical bridging is adequate.

Strategy 3: Use an albumin-bound or protein-associated platform

Protein-associated docetaxel systems can seek differentiation through reduced solvent exposure and altered biodistribution. The commercial precedent is strongest in the broader taxane class, where albumin-bound paclitaxel demonstrates that solvent reduction can support a distinct product profile.

Docetaxel cannot rely on paclitaxel precedent alone. The sponsor must establish product-specific chemistry, manufacturing and controls, pharmacokinetics, safety, and efficacy. Protein source, particle architecture, residual process materials, aggregation, and storage stability become central development issues.

Strategy 4: Enable oral or depot delivery

Oral docetaxel is attractive because it could reduce infusion-center use and support combination regimens. The principal barriers are intestinal permeability, efflux transport, first-pass metabolism, variable absorption, and gastrointestinal toxicity.

Relevant excipient approaches include lipid-based formulations, self-emulsifying systems, permeation enhancers, mucoadhesive systems, amorphous solid dispersions, and transporter-modulating combinations. These systems may require a new drug application or a substantial clinical development program rather than a simple generic pathway.

Long-acting injectable systems are technically possible but commercially more difficult. Docetaxel’s toxicity, dose scheduling, and need for rapid treatment discontinuation reduce the attractiveness of depot release unless the system provides a strong exposure or adherence advantage.

What formulations are protected by docetaxel patents?

Docetaxel’s basic composition-of-matter and original formulation exclusivity have expired in major markets. The commercial market is therefore dominated by generic intravenous products. Current value is more likely to reside in later-generation formulation, delivery, manufacturing, and method-of-use claims.

Patent category	Commercial relevance	Current risk profile
Docetaxel composition of matter	Protects the molecule itself	Generally expired
Polysorbate 80/ethanol injection	Covers legacy presentation or process elements	Limited blocking value where claims have expired
Nanoparticle or liposomal formulation	Protects carrier architecture and composition	Potentially material for differentiated products
Oral formulation	Covers absorption-enhancing and dosage-form technology	Potentially material
Dosing or combination method	Covers selected regimens or patient groups	Dependent on claim scope and jurisdiction
Manufacturing process	Covers impurity control, crystallization, particle engineering or sterile processing	Important for supply and freedom to operate
Container and administration system	Covers ready-to-use or device-linked products	Relevant to hospital procurement

A formulation patent may be commercially weak if it claims only a narrow excipient ratio, lacks enforceable claims in key markets, or can be designed around without changing clinical performance. Stronger estates typically combine composition claims, process claims, particle or carrier parameters, and clinical-use claims.

When does docetaxel lose exclusivity and what is the Orange Book status?

Taxotere was approved by FDA in 1996 under NDA 020449.[1] Docetaxel is now available from multiple generic manufacturers in injectable form. The active ingredient does not have biosimilar exclusivity because docetaxel is a chemically synthesized small molecule, not a biologic.

FDA’s Orange Book identifies approved drug products and relevant patent and exclusivity information. For docetaxel, the practical market position is that legacy product exclusivity has ended and generic competition is established.[2] Any current product-specific patent analysis must be performed at the NDA, formulation, strength, dosage-form, and jurisdiction level because an approved product’s listed patents can change over time.

Paragraph IV challenges were commercially important during the transition from Taxotere to generic docetaxel. They are less central to ordinary market entry today than they would be for a newly protected reformulation. A new formulation sponsor should expect Paragraph IV risk if its product is listed in the Orange Book and generic applicants can certify that asserted patents are invalid, unenforceable, or not infringed.

What FDA regulatory pathway applies to a new docetaxel formulation?

A conventional product that is pharmaceutically equivalent and bioequivalent to an approved reference product may qualify for an abbreviated new drug application. A product with a materially different excipient system, delivery platform, concentration, route, or clinical profile may require a 505(b)(2) application.

Product concept	Likely U.S. pathway
Same active, route, dosage form and equivalent formulation	ANDA, subject to applicable reference-product requirements
Reduced-solvent injectable with changed excipient system	Often 505(b)(2), depending on equivalence
Nanoparticle or liposomal docetaxel	Generally 505(b)(2) or full NDA-type development
Oral docetaxel	505(b)(2) or full development, depending on reliance and differences
New combination or dosing regimen	505(b)(2), supplemental NDA or full clinical program
Generic injectable manufacturing change	ANDA supplement if the approved product remains within the applicable framework

FDA’s product-specific guidance and pharmaceutical equivalence requirements should drive the development plan. A formulation that changes exposure or biodistribution materially cannot assume that conventional bioequivalence will be sufficient.[3]

How strong is the patent estate for docetaxel anhydrous?

The patent estate for the basic molecule is weak from a blocking perspective because the product is mature and genericized. The estate for differentiated delivery systems can be stronger, but strength depends on claim breadth and clinical value.

A commercially useful patent package should cover:

1. The active-excipient composition.
2. Particle size, morphology, or carrier structure.
3. Drug loading and release behavior.
4. Manufacturing and sterilization conditions.
5. Storage and dilution stability.
6. Administration and dosing methods.
7. Patient selection or reduced-premedication use.
8. A ready-to-use presentation or administration device.

Manufacturing IP may be particularly valuable. Docetaxel products require control of related substances, residual solvents, polymorphic or hydrate state, sterile filtration, aseptic processing, and container compatibility. A process that improves yield or reduces impurity formation can protect margin even when composition claims are narrow.

Geographic coverage should prioritize the United States, European Union, Japan, China, Canada, South Korea, Australia, Brazil, and major oncology markets. Patent term, patentability standards, regulatory linkage, and generic litigation procedures differ substantially across these jurisdictions.

Which companies are competing in docetaxel formulations?

The conventional market includes the originator Sanofi and numerous generic manufacturers, including large injectable suppliers and regional oncology manufacturers. Competition is based mainly on price, supply reliability, regulatory compliance, vial sizes, concentration, and hospital contracting.

The more attractive competitive space is differentiated delivery. Potential competitors include:

• Specialty oncology companies developing solvent-reduced taxanes
• Nanomedicine companies with liposomal or polymeric carrier platforms
• Generic manufacturers seeking 505(b)(2) reformulations
• Contract development and manufacturing organizations with sterile nanoparticle capability
• Drug-delivery companies with oral absorption technologies

Direct comparison should focus on clinical and operational outcomes rather than excipient novelty alone.

Attribute	Conventional docetaxel injection	Differentiated formulation opportunity
Solubilizer	Polysorbate 80	Reduced or eliminated
Ethanol	Usually present in concentrate	Potentially eliminated
Preparation	Dilution required	Ready-to-use possible
Premedication	Commonly required	Reduction may be a clinical objective
Manufacturing	Established	More complex
Regulatory risk	Lower for generic approach	Higher
Gross-margin potential	Low to moderate	Moderate to high if clinically differentiated
Patent value	Limited for legacy system	Higher for protected platform

What commercial opportunities exist for docetaxel anhydrous?

The most credible opportunities are hospital products with measurable workflow or safety benefits.

Ready-to-use injectable

A stable, pre-diluted product could reduce pharmacy preparation time, occupational exposure, compounding error risk, and waste. Commercial value would depend on refrigerated shelf life, bag or syringe compatibility, concentration flexibility, and reimbursement treatment.

Solvent-reduced product

A formulation that reduces polysorbate 80 and ethanol may gain adoption if it lowers infusion reactions, premedication requirements, or chair time. The clinical claim must be demonstrated rather than inferred from excipient removal.

High-concentration formulation

A higher-strength product could reduce infusion volume and administration time. The development burden includes precipitation control, infusion tolerability, local tolerability, and dose accuracy.

Nanoparticle product

A carrier-based product can command a premium if it improves pharmacokinetics, tolerability, or treatment convenience. Without a demonstrated clinical advantage, it risks competing against low-cost generic docetaxel while carrying higher manufacturing costs.

Oral product

An oral formulation could access outpatient and combination-treatment markets, but it faces the highest clinical and regulatory risk. It would compete on convenience and potentially new treatment settings rather than on generic price.

What generic launch risks exist for a new formulation?

A new docetaxel product faces five principal launch risks:

• Generic substitution if the formulation is viewed as clinically interchangeable
• Patent design-around by injectable competitors
• Unfavorable reimbursement for premium formulations
• Manufacturing failures involving particles, sterility, or aggregation
• Failure to prove lower hypersensitivity or reduced premedication requirements

Settlement agreements and Paragraph IV litigation remain relevant if a new formulation receives Orange Book-listed patents. However, commercial protection will depend on enforceable claims that cover the marketed presentation, not only laboratory embodiments.

Key Takeaways

• Docetaxel anhydrous is a mature, genericized small-molecule taxane.
• The conventional excipient system relies on polysorbate 80 and ethanol, creating formulation and tolerability targets.
• The highest-value opportunities are solvent reduction, ready-to-use presentations, nanoparticle delivery, and oral absorption technologies.
• Basic molecule patents do not provide meaningful current exclusivity in major markets.
• New formulation value must come from clinically demonstrated improvements in safety, preparation, exposure, or administration time.
• A differentiated product will often require a 505(b)(2) strategy rather than a conventional ANDA.
• Patent strength depends on formulation, process, dosage-form, and method-of-use claims that are difficult to design around.
• Docetaxel has no biosimilar pathway because it is not a biologic.
• Commercial success will depend on hospital workflow economics, supply reliability, reimbursement, and evidence of reduced excipient-related burden.

FAQs About Docetaxel Anhydrous Excipient and Patent Strategy

Can polysorbate 80 be removed from docetaxel injection?

Yes, but removal requires a replacement solubilization or delivery system that preserves concentration, stability, sterility, dilution behavior, and clinical tolerability.

Is ethanol necessary in docetaxel formulations?

No. Ethanol is used as a co-solvent in conventional products, but alternative systems may reduce or eliminate it if the active remains physically and chemically stable.

Can a docetaxel formulation receive new patent protection?

Yes. New patents may cover nanoparticles, excipient combinations, particle attributes, oral dosage forms, manufacturing processes, ready-to-use presentations, or specific treatment methods.

Does docetaxel require biosimilar approval?

No. Docetaxel is a synthetic small molecule. Competing products generally use generic drug approval pathways or, for materially changed formulations, a 505(b)(2) application.

What is the most attractive commercial formulation for docetaxel?

A solvent-reduced, ready-to-use intravenous product has the clearest near-term commercial rationale because it targets existing oncology workflows while avoiding the full risk of oral or long-acting delivery.

References

1. U.S. Food and Drug Administration. (2024). Taxotere (docetaxel) injection, prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2022). Draft guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant origin.
4. European Medicines Agency. (2024). Docetaxel-containing medicinal products: Product information and regulatory records.
5. National Cancer Institute. (2024). Docetaxel. NCI Drug Dictionary.